ERBB2 and breast carcinoma: We first optimized and demonstrated the potential of the on-chip quantification of HER2-HER3 dimerization at the single-cell level using cancer cell lines, and further demonstrated its implementation on blood samples from breast cancer patients treated or not with HER2-targeted therapy.